Capivasertib + Abiraterone for Prostate Cancer

(SNARE Trial)

Recruiting at 5 trial locations

Overseen By Ryan P Kopp, MD

Age: 18+

Sex: Male

Trial Phase: Phase 2

Sponsor: VA Office of Research and Development

Must be taking: Androgen deprivation drugs

Must not be taking: Anti-androgens, Chemotherapy

Disqualifiers: Uncontrolled diseases, Active infections, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 16 weeks

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new combination of medications to treat high-risk prostate cancer that hasn't spread. The goal is to determine if taking capivasertib (also known as Truquap or AZD-5363) with other drugs, such as abiraterone acetate (also known as Zytiga), before surgery can shrink or destroy tumors effectively and safely. Participants must have a confirmed diagnosis of prostate cancer with certain high-risk features, like a high PSA level or specific tumor characteristics. This trial targets those considering surgery who have been informed about other options, like radiotherapy, but have chosen surgery. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop your current medications. However, you cannot take certain medications like potent inhibitors or inducers of CYP3A4, drugs that prolong the QT interval, or any medication that may interfere with abiraterone. It's best to discuss your current medications with the trial team to see if they are allowed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that most people can generally handle the combination of capivasertib and abiraterone. Studies have found that the side effects are usually mild.

Common side effects from past studies include kidney problems, high blood sugar, skin rash, stomach pain, and tiredness. These were more serious for a small number of people. It's important to know that these side effects are similar to those seen when using these drugs individually.

Overall, evidence suggests that this treatment is safe for many people, but individual reactions may vary. Always consult a healthcare provider about the potential risks and benefits before joining a trial. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for prostate cancer?

Researchers are excited about Capivasertib combined with Abiraterone for prostate cancer because this combination targets the cancer in a novel way. Unlike standard treatments, which typically focus on reducing testosterone to slow cancer growth, Capivasertib is an AKT inhibitor. This means it directly interferes with the cancer cell growth pathways, potentially making the treatment more effective. By combining Capivasertib with Abiraterone, which already disrupts the androgen receptor pathway, this approach might attack the cancer on multiple fronts, offering new hope for patients.

What evidence suggests that this trial's treatments could be effective for prostate cancer?

Research has shown that using capivasertib with abiraterone might help treat certain types of prostate cancer. Studies found that this combination can slow the cancer's progression. Patients with a specific type of prostate cancer, called PTEN-deficient, experienced better results with this treatment. Specifically, it helped them live longer without their cancer worsening. This trial will evaluate the combination of capivasertib with abiraterone, suggesting it could be a promising option for difficult-to-treat prostate cancer. ^{1 3 4 5 6}

Who Is on the Research Team?

Ryan P Kopp, MD

Principal Investigator

VA Portland Health Care System, Portland, OR

Are You a Good Fit for This Trial?

Men over 18 with high-risk, non-metastatic prostate cancer that's not spread beyond the prostate and has specific genetic features (PTEN loss). They should have a life expectancy of more than 10 years, be able to take oral medication, and have no severe health issues. Men must use condoms if with a partner who can bear children. Those with active hepatitis or HIV, other cancers, significant heart disease or recent major surgery aren't eligible.

Inclusion Criteria

I am willing to give a tissue sample for testing.

I am scheduled for prostate surgery with lymph node removal.

I am a man who will use birth control when with a woman who can have children.

Exclusion Criteria

I have had treatments for prostate cancer, including hormone therapy, radiation, or chemotherapy.

Clinically significant abnormalities of glucose metabolism

I have not had major surgery or a serious injury recently.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Run-in

Eligible patients undergo a 4-week run-in of intensified androgen deprivation therapy (iADT)

4 weeks

Treatment

Participants receive 16 weeks of combined iADT with AKT inhibition (capivasertib) prior to radical prostatectomy

16 weeks

Surgery

Participants undergo radical prostatectomy with assessment of pathological response

1 week

Follow-up

Participants are monitored for treatment-related adverse events and surgical complications

3 months

What Are the Treatments Tested in This Trial?

Interventions

• Abiraterone Acetate
• Capivasertib

Trial Overview

The trial is testing whether taking capivasertib along with intensified hormone therapy drugs (abiraterone acetate and leuprolide) before surgical removal of the prostate can shrink tumors in men whose cancer hasn't spread but is at high risk for progression.

How Is the Trial Designed?

Group I: Single Arm Experimental Treatment 2 Interventions

neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials

1,691

Recruited

3,759,000+

Published Research Related to This Trial

In a phase 3 trial with a median follow-up of 20.2 months, patients with metastatic castration-resistant prostate cancer who received abiraterone acetate and prednisone experienced significantly greater pain relief compared to those receiving prednisone alone, with 45% achieving pain palliation versus 28.8%.

Abiraterone acetate and prednisone also delayed the occurrence of skeletal-related events, with a median time of 25 months compared to 20.3 months for prednisone alone, indicating a substantial benefit in managing complications associated with bone metastases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Logothetis, CJ., Basch, E., Molina, A., et al.[2022]

A study involving 32 healthy male subjects demonstrated that the test product (abiraterone acetate tablet) is bioequivalent to the reference product ZYTIGA® in terms of pharmacokinetics, with both products showing similar maximum concentration (Cmax) and area under the curve (AUC) values within the acceptable range.

The research confirmed significant intra-subject variability in the pharmacokinetics of abiraterone, indicating that individual responses to the drug can vary widely, which is important for clinicians to consider when prescribing.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. Wang, C., Hu, C., Gao, D., et al.[2022]

Abiraterone acetate significantly improves overall survival and radiographic progression-free survival in men with metastatic castration-resistant prostate cancer (CRPC) when combined with prednisone, based on results from a multinational phase III study involving men who had previously received docetaxel.

The treatment is generally well-tolerated, although it can cause side effects like hypokalaemia and hypertension; however, serious adverse events were relatively low in the phase III studies, indicating it is a viable option for managing metastatic CRPC.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Hoy, SM.[2021]

In a study of 54 metastatic castration-resistant prostate cancer patients, cabazitaxel showed a PSA reduction rate of over 50% in 46.2% of patients, with a disease control rate of 83.3% after 3 months, although it had significant side effects like neutropenia in 40% of patients.

Abiraterone resulted in a PSA reduction rate of 35.1% and a disease control rate of 47.1%, with lower rates of severe hematotoxicities but higher rates of fatigue and other non-hematological side effects, indicating both treatments are effective with manageable side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. Heck, MM., Höppner, M., Horn, T., et al.[2021]

Abiraterone acetate (Zytiga®) is an effective antiandrogen for prostate cancer but has poor oral bioavailability (<10%) and requires patients to fast around its administration due to a significant food effect (5-10-fold increase in absorption).

The review highlights the need for improved oral formulation strategies to enhance solubility and bioavailability of abiraterone acetate, aiming to reduce the required dose and eliminate the food effect, which could lead to better patient compliance.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Schultz, HB., Meola, TR., Thomas, N., et al.[2020]

Abiraterone acetate has been shown to significantly increase survival rates in patients with metastatic castration-resistant prostate cancer, making it a key treatment option for this condition.

Recent studies indicate that abiraterone acetate is also effective when combined with androgen deprivation therapy for metastatic castration-sensitive prostate cancer, expanding its use in earlier stages of the disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. Caffo, O., Veccia, A., Kinspergher, S., et al.[2018]

Abiraterone acetate is the first second-line hormonal treatment shown to improve survival in metastatic castration-resistant prostate cancer, initially approved in 2011 for patients who had not responded to docetaxel, showing a 4-month survival benefit.

The FDA has expanded its use to the pre-chemotherapy setting due to significant delays in disease progression and trends toward increased overall survival, with ongoing studies investigating its effectiveness in earlier stages and in combination with other treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Harshman, LC., Taplin, ME.[2021]

Oral abiraterone acetate (Zytiga®) significantly improves overall survival and progression-free survival in patients with metastatic castration-resistant prostate cancer (CRPC) when used with prednisone, compared to a placebo.

The treatment is specifically effective for patients who have already undergone docetaxel-containing chemotherapy, highlighting its role as a subsequent therapy in advanced prostate cancer management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. Scott, LJ., Yang, LPH., Lyseng-Williamson, KA.[2021]

Citations

1.

annalsofoncology.org

annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext

Capivasertib plus abiraterone in PTEN-deficient metastatic ...

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015; 67:795-802.

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S0923753425049361

Capivasertib plus abiraterone in PTEN-deficient metastatic ...

In the randomized PTEN-deficient population, a statistically significant improvement in rPFS was observed with capivasertib plus abiraterone (n= ...

3.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/36572571/

A Phase I Study of Capivasertib in Combination With ...

These data support further evaluation of capivasertib and abiraterone acetate in patients with advanced prostate cancer.

4.

astrazeneca-us.com

astrazeneca-us.com/media/press-releases/2024/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-radiographic-progression-free-survival-in-capitello-281-phase-iii-trial.html

TRUQAP® (capivasertib) combination in PTEN-deficient ...

TRUQAP (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful ...

5.

onclive.com

onclive.com/view/capivasertib-plus-abiraterone-acetate-prednisone-and-adt-extends-rpfs-in-pten-deficient-hspc

Capivasertib Plus Abiraterone Acetate, Prednisone, and ...

The median symptomatic skeletal event-free survival was 42.5 months with capivasertib compared with 37.3 months for placebo. Events for this end ...

6.

astrazeneca.com

astrazeneca.com/content/astraz/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer.html

Truqap combination in PTEN-deficient metastatic hormone- ...

AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and ...